Looking to list your PhD opportunities? Log in here.
About the Project
We reported that silencing the WNT receptor ROR2 results in protection from cartilage breakdown and rapid pain relief in a murine model of osteoarthritis and in chondrogenesis in vitro and in vivo with human osteoarthritic chondrocytes (Thorup et al. Sci Transl Med 2020). We have now developed a recombinant molecule that that blocks ROR2 and is chondrogenic in vitro. With this application we want to further optimise this molecule to extend its half-life in vivo and we aim at providing efficacy data in animal models of osteoarthritis.
Applications should be sent directly to QMUL admissions via this link (choosing the category: PhD Full-time William Harvey Research Institute (non-clinical) Semester 1 (September Start)):
https://www.qmul.ac.uk/postgraduate/research/subjects/medicine-william-harvey-research-institute.html
The closing date for applications is Wednesday 20th July 2022, interviews will be thereafter. Start date is 1st September 2022
Funding Notes
References
How good is research at Queen Mary University of London in Clinical Medicine?
Research output data provided by the Research Excellence Framework (REF)
Click here to see the results for all UK universities
Search suggestions
Based on your current searches we recommend the following search filters.
Check out our other PhDs in London, United Kingdom
Check out our other PhDs in United Kingdom
Start a New search with our database of over 4,000 PhDs

PhD suggestions
Based on your current search criteria we thought you might be interested in these.
Development of an isolated glomerular albumin permeability assay to high throughput for drug screening in human glomerular disease
University of Bristol
Uromodulin a Precision Medicine Target for Novel Drug Discovery in Cardiovascular Disease
University of Glasgow
Screening of chemical libraries using iPS models for investigating the role of prion protein in Alzheimer’s disease
University of Sheffield